Mechanisms of Relapse Prevention in Schizophrenia

 

 Buy Article Permissions and Reprints

Introduction: A relapse can be expected in 70 % of patients after the first schizophrenic episode; in parallel 70 % of patients show an incomplete remission of the disorder after the first episode. This includes a cognitive decline and persistence of schizophrenic negative symptoms, often associated with social disabilities, social decline and a worsened quality of life. The risk for a relapse after a schizophrenic episode remains increased throughout the patient’s lifetime. Moreover, the risk for chronic disorder increases with every relapse of the patient. Therefore relapse prevention is a primary focus in the treatment of schizophrenia. Methods: Studies point out that atypical antipsychotics have advantages in relapse prevention of schizophrenia compared to the ‘classical’ antipsychotics, although comparative studies are still lacking. Results: The main risk factor for a relapse is the withdrawal of antipsychotic medication. Nonbiological factors such as high-expressed emotions, adverse life events and stress contribute to an increased risk of schizophrenic relapse. Studies of relapse after withdrawal of antipsychotic medication revealed that noradrenergic, serotonergic, and dopaminergic neurotransmission are involved, low serotonergic and high dopaminergic neurotransmission are associated with a relapse, and possibly high noradrenergic neurotransmission plays a role in short-term relapses. Inflammation and the activation of certain cytokines, which have rarely been studied to date, seem to have an even higher impact on schizophrenic relapse. Methodological aspects of these studies are discussed. Conclusion: Biological mechanisms of relapse may not become fully elucidated before the mechanisms of the schizophrenic pathophysiology are clarified.

References

• 1 American Psychiatric A ssociation. Practise guideline for the treatment of patients with schizophrenia.  Am J Psychiatry. 1997;  154 (Suppl 4) S1-S63
  PubMedGoogle Scholar
• 2 Angrist B, Peselow E, Rotrosen J, Gershon S. Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects.  Rec Adv Neuropsychopharmacol Adv Biosci. 1981;  31 49-54
  PubMedGoogle Scholar
• 3 Bailer J, Rist F, Brauer W, Rey E R. Patient rejection scale: correlations with symptoms, social disability and number of re-hospitalizations.  Eur Arch Psychiatry Clin Neurosci. 1994;  244 45-48
  PubMedGoogle Scholar
• 4 Bebbington P, Kuipers L. The predictive utility of expressed emotions in schizophrenia: an aggregate analysis.  Psychol Med. 1994;  24 707-718
  Google Scholar
• 5 Bosveld-van Haandel L JM, Slooff C J, van den Bosch R J. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.  Acta Psychiatr Scand. 2001;  103 335-346
  CrossrefPubMedGoogle Scholar
• 6 Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
  CrossrefPubMedGoogle Scholar
• 7 Davidson M, Keefe R SE, Mohs R, Siever L J, Losonczy M F, Horvarth T B, Davis K L. L-dopa challenge and relapse in schizophrenia.  Am J Psychiatry. 1987;  144 934-938
  PubMedGoogle Scholar
• 8 Davis J M, Mentalon L, Watanabe M D. Depot antipsychotic drugs: place in therapy.  Drugs. 1994;  47 741-773
  CrossrefPubMedGoogle Scholar
• 9 Docherty J P, van Kammen D P, Siris S G, Marder S T. Stages of onset of schizophrenic psychoses.  Am J Psychiatry. 1978;  135 420-426
  PubMedGoogle Scholar
• 10 Doering S, Müller E, Köpcke W, Pietzcker A, Gaebel W, Linden M, Müller P, Müller-Spahn F, Tegeler J, Schüssler G. Predictors of relapse and re-hospitalization in schizophrenia and schizoaffective disorder.  Schizophrenia Bull. 1998;  24 87-98
  PubMedGoogle Scholar
• 11 Dutch Schizophrenia F oundation. Consensus document. The Netherlands; Schizophrenia Foundation 1996
  Google Scholar
• 12 Gaebel W, Falkai P (eds.) Praxisleitlinien in Psychiatrie und P sychotherapie. Behandlungsleitlinie Schizophrenie. Darmstadt; Steinkopff-Verlag 1998
  Google Scholar
• 13 Gattaz W F, Abrahao A L, Foccacia R. Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci 2003 (in press)
  Google Scholar
• 14 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  Br Med J. 2000;  321 1371-1376
  CrossrefPubMedGoogle Scholar
• 15 Glazer W M, Kane J M. Depot neuroleptic therapy: an underutilized treatment option?.  J Clin Psychiatry. 1992;  53 426-433
  PubMedGoogle Scholar
• 16 Hogarty G E. Prevention of relapse in chronic schizophrenic patients.  J Clin Psychiatry. 1993;  54 (Suppl 3) 18-23
  PubMedGoogle Scholar
• 17 Hogarty G E, Schooler N R, Ulrich R F, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a two-year controlled study of fluphenazine-decanoate and fluphenazine hydrochloride.  Arch Gen Psychiatry. 1979;  36 1283-1294
  CrossrefPubMedGoogle Scholar
• 18 Kelley M E, Yao J K, van Kammen D P. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in Schizophrenia.  Neuropsychopharmacol. 1999;  20 603-611
  PubMedGoogle Scholar
• 19 Kissling W ( ed). Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin, NY; Springer Verlag 1991
  Google Scholar
• 20 Kissling W, Kane J M, Barnes T R, Dencker K, Fleischhacker W W, Goldstein J M, Johnsom D AW, Marder S R, Müller-Spahn F, Tegeler J, Wilstedt B, Woggon B. Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. in: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin, NY; Springer Verlag 1991: pp 155-163
  Google Scholar
• 21 Leucht S, Barnes T RE, Kissling W, Engel R R, Correll C, Kane J M. Relapse prevention in schizophenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.  Am J Psychiatry. 2003;  160 1209-1222
  Google Scholar
• 22 Lieberman J A, Kane J M, Gadaletta D. Methylphenidate challenge tests and course of schizophrenia.  Psychopharmacol Bull. 1985;  21 123-129
  PubMedGoogle Scholar
• 23 Lieberman JA Koreen A R, Chakos M, Sheitman B, Woerner M, Alvir J MJ, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry. 1996;  57 (Suppl 9) 5-9
  PubMedGoogle Scholar
• 24 McEvoy J P, Scheifler P L, Frances A ( eds). The expert consensus guideline series. Treatment of schizophrenia 1999.  J Clin Psychiatry. 1999;  60 (Suppl 11)
  PubMedGoogle Scholar
• 25 Müller N. Neuroimmunology of schizophrenia. In: D’Haenen H, den Boer JA, Willner P (eds) Biol Psychiatry. J Wiley & Sons 2002: pp 613-623
  Google Scholar
• 26 Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine-network in the CNS: implications for psychiatric disorders.  Prog Neuropsychopharmacol Biol Psychiatry. 1998;  22 1-33
  CrossrefPubMedGoogle Scholar
• 27 Müller N, Riedel M, Scheppach C, Brandstätter B, Sokkullu S, Krampe K, Ulmschneider M, Möller H -J, Schwarz M. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.  Am J Psychiatry. 2002;  159 1029-1034
  CrossrefPubMedGoogle Scholar
• 28 Müller N, Ulmschneider M, Scheppach C, Schwarz M J, Ackenheil M, Möller H -J, Gruber R, Riedel M. COX-2 Inhibition as Treatment Approach in Schizophrenia: Immunological Considerations and Clinical Effects of Celecoxib add-on Therapy.  Eur Arch Psychiatry Clin Neurosci. 2004;  254 14-22
  CrossrefPubMedGoogle Scholar
• 29 Müller-Spahn F. Neuroendokrinologie und Schizophrenieforschung. Berlin, NY; Springer Verlag 1989
  Google Scholar
• 30 McAllister C G, van Kammen D P, Rehn T J, Miller A L, Gurklis J A, Kelley M D, Yao J K, Peters J F. Increases in CSF levels of Interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.  Am J Psychiatry. 1995;  152 1291-1297
  PubMedGoogle Scholar
• 31 Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: alomgitudinal study.  Acta Psychiat Scand. 1994;  (Suppl 382) 58-64
  PubMedGoogle Scholar
• 32 Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.  Am J Psychiatry. 2001;  158 266-269
  CrossrefPubMedGoogle Scholar
• 33 Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up.  Int J Epidemiol. 1997;  26 837-843
  CrossrefPubMedGoogle Scholar
• 34 Robinson D, Woerner M G, Alvir J MJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman J A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.  Arch Gen Psychiatry. 1999;  56 241-247
  CrossrefPubMedGoogle Scholar
• 35 Sartorius N, Gulbinat W, Harrison G, Laska G, Siegel C. Long-term follow-up of schizophrenia in 16 countries: a description of the International Study of Schizophrenia conducted by the World Health Organisation.  Soc Psychiatry Psychiatr Epidemiol. 1996;  31 249-258
  PubMedGoogle Scholar
• 36 Schaub A. Relapse and coping behavior in schizophrenia.  Schizophrenia Res. 1994;  11 188
  PubMedGoogle Scholar
• 37 Schaub A. Coping-Forschung und bewältigungsorientierte Therapien bei schizophrenen Störungen. In: Bäuml J, Pitschl-Walz G (Hrsg) Psychoedukation bei schizophrenen Erkrankungen. Schattauer. Stuttgart, NY; 2003: pp 173-203
  Google Scholar
• 38 Szymanski H V, Simon J C, Gutterman N. Recovery from schizophrenic psychosis.  Am J Psychiatry. 1983;  140 335-338
  PubMedGoogle Scholar
• 39 van Kammen D P, Kelley M D, Gurklis J A, Gilbertson M K, Yao J K, Peters J F. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.  Arch Gen Psychiatry. 1995;  52 673-678
  PubMedGoogle Scholar
• 40 van Kammen D P, Kelley M D, Gurklis J A, Gilbertson M K, Yao J K, Condray R, Peters J F. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.  Neuropsychopharmacol. 1996;  14 603-611
  PubMedGoogle Scholar
• 41 van Kammen D P, Peters J F, van Kammen W B, Nugent A, Goetz K L, Yao J K, Linnoila M. CSF Norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 1989: 176-188
  Google Scholar
• 42 Wiersma D, Nienhuis F J, Sloof C J, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort.  Schizophr Bull. 1998;  24 75-85
  CrossrefPubMedGoogle Scholar
• 43 Zhang-Wong J, Beiser M, Bean G, Iacono W G. Five-year course of schizophreniform disorder.  Psychiatry Res. 1995;  59 109-117
  CrossrefPubMedGoogle Scholar
• 44 Zubin J, Steinhauer S R, Day R, van Kammen D P. Schizophrenia at the crossroads: A blueprint of the 80’s.  Compr Psychiatry. 1985;  26 217-240
  CrossrefPubMedGoogle Scholar

Prof. Dr. med. Dipl.-Psych. Norbert Müller

Department of Psychiatry and Psychotherapy

Ludwig-Maximilians University

Nußbaumstr. 7

80336 Munich

Germany

Phone: +49 89 5160 3397

Fax: +49 89 5160 4548

Email: norbert.mueller@med.uni-muenchen.de